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The recent ‘regulatory noise’ around the prospect of the agricultural 
commercialisation of cloned animals and/or their offspring as expressed in reports by 
the US Food and Drug Administration, the European Group on Ethics (EGE) on 
Science and New Technologies and the European Food Safety Authority (EFSA) 
suggests that finally the time is upon us to consider the prospect of emerging breeding 
technologies (EBTs) in animal production. 
 
By ‘us’ one could mean not only regulatory bodies but also a wide range of academics 
and ‘publics’. To what extent are molecular technologies such as genomics, GM and 
cloning the latest capitalist accumulation strategies within the industrialisation of 
animal production? Do they reinvent our already ambivalent relationship to farmed 
animals, and what effect may they have upon the experiential realities of the - 
typically short - lives of farmed animals? How may they refigure the relationship 
between breeder and animal? Can they, as their proponents suggest, really make 
meaningful contributions to sustainable agricultures? Or are they incredibly badly 
timed technologies arriving just when the cultural interest in animal welfare 
intensifies and the health and environmental costs of animal consumption and 
production are to the fore? 
 
One thing I think is clear. Many among the community of social scientists and 
philosophers have got things wrong. They take the substantive and moral bifurcation 
between ‘green’ and ‘red’ biosciences as read, failing to see the points of 
interconnection between the ‘agricultural’ and the ‘medical’. Cloning is, of course, a 
great example. The main US animal cloning company Viagen, which has generously 
supplied data to the FDA deliberation and travelled all the way to Brussels to speak to 
the EGE workshop, owns the IPR on the cloning techniques originally associated with 
the Roslin Institute research that produced Dolly the Sheep. This research was aimed 
at human medical applications and did not foreground agricultural applications. This 
is just one example of why researchers beavering away on the ‘red’ (or the ‘green’) 
biosciences should think more critically about this arguably false separation as it is, 
first, certainly a hangover from our epistemological culture/nature differentiating 
legacies, and, second, increasingly being rendered useless by research into such 
hybrid entities as biopharmed animals, xenotransplants and animal/human embryos.  
 
Genomics, Society and Policy purposively makes itself open to a wide range of 
disciplines and approaches. This includes providing an outlet for papers that go 
beyond the red-green split, and acting as a corrective to the over-emphasis on the 
human medical domain – constructed as somehow sealed off hermetically from the 
nonhuman. In 2007, then, we have already produced a special issue on Animal 
Genomics, a theme that is continued in this present issue with a paper on GM animals. 
Also included in the issue are papers on public health genomics, aspects of the doctor-
patient relationship and a focus on a recent bioethical concept of interest. We hope 
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that you enjoy the diversity of the issue and we look forward to more interesting 
submissions in 2008, as well your ideas for innovative special issues. 
 
Richard Twine 
ESRC Centre for Economic and Social Aspects of Genomics, Lancaster University, 
UK 
Associate Editor 
